A vaccine adjuvant is defined as an agent that increases specific immune responses to an antigen [200]. The only vaccine adjuvants currently licensed by the FDA are aluminium salts. All other adjuvants are considered experimental and must undergo special preclinical testing. Real and theoretical risks of vaccine adjuvants comprise various local acute or chronic inflammation with formation of abscesses and nodules; induction of hypersensitivity to the host’s own tissues, producing autoimmune arthritis, amyloidosis, anterior uveitis; cross-reactions with human antigens, such as glomerular basement membranes or neurolemma, causing glomerulonephritis or meningoencephalomyelitis; sensitization to tuberculin or to other skin test antigens; carcinogenesis; pyogenesis; teratogenesis; abortion; and adverse pharmacological effects, such as hypoglycemia.